{"product_id":"a-one-time-gene-editing-treatment-for-high-cholesterol-shows-strong-results-at-1-year-what-the-new-ctx310-data-mean","title":"A One-Time Gene-Editing Treatment for High Cholesterol Shows Strong Results at 1 Year: What the New CTX310 Data Mean","description":"\u003cp\u003eResearchers report that a single infusion of the experimental gene-editing therapy CTX310 produced large, lasting reductions in blood fats (lipids) at 1 year in patients with severe cholesterol and triglyceride disorders. In the four patients who received the highest dose, mean levels of ANGPTL3 — a liver protein that regulates fat metabolism — fell by 78.6%, LDL (\"bad\") cholesterol by 52.5%, and triglycerides by 47.8%, with no new safety concerns. The study is an early-phase, open-label trial with only 15 participants, so these durability results require confirmation in larger studies, but they strengthen the case that a one-time treatment could someday replace daily lipid-lowering pills. This patient article explains the methods, the full set of results, and what these findings may mean for people living with lipid disorders.\u003c\/p\u003e\n\n\u003ch1\u003eA One-Time Gene-Editing Treatment for High Cholesterol Shows Strong Results at 1 Year: What the New CTX310 Data Mean\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#why-it-matters\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#study-methods\"\u003eHow the Study Was Designed\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#how-ctx310-works\"\u003eHow CTX310 Works: The Science Explained\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#safety\"\u003eSafety at 1 Year: What the Researchers Found\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#efficacy\"\u003eEffectiveness at 1 Year: Detailed Results\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#other-approaches\"\u003eOther Gene-Editing Approaches for Lipid Disorders\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Could Mean for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#next-steps\"\u003eWhat Happens Next\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eA single infusion of gene-editing therapy CTX310 lowered LDL cholesterol by 52.5% and triglycerides by 47.8% at 1 year in 4 patients at the highest dose.\u003c\/li\u003e\n\u003cli\u003eCTX310 disables the ANGPTL3 gene in the liver, mimicking naturally occurring genetic mutations that protect people from heart disease.\u003c\/li\u003e\n\u003cli\u003eIn this 15-patient early trial, no dose-limiting toxic effects and no new safety concerns appeared over the first year of follow-up.\u003c\/li\u003e\n\u003cli\u003eThe treatment is experimental and only available in clinical trials; patients should continue prescribed lipid-lowering medications until doctors advise otherwise.\u003c\/li\u003e\n\u003cli\u003eOne-year results are encouraging but not definitive—larger studies are needed to confirm durability, safety, and which patient subgroups benefit most.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"why-it-matters\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eHeart attacks and strokes are often driven by atherosclerosis — the buildup of cholesterol-filled plaque inside arteries. Many patients lower their risk with daily statin pills and other medications. Yet some people cannot reach healthy cholesterol targets, and daily lifelong treatment is a burden for many others.\u003c\/p\u003e\n\n\u003cp\u003eGene editing offers a radical alternative. The idea is simple: instead of taking a drug every day for decades, a patient would receive one treatment that permanently disables a specific gene in the liver, changing how the body handles cholesterol from that point forward.\u003c\/p\u003e\n\n\u003cp\u003eThe new research focuses on CTX310, an experimental therapy that edits the gene for ANGPTL3 (angiopoietin-like protein 3). ANGPTL3 is a protein made in the liver that normally acts as a brake on the enzymes that clear fats from the blood. When that brake is removed — by a natural genetic variation or by gene editing — the liver produces less ANGPTL3, and levels of harmful fats in the bloodstream drop.\u003c\/p\u003e\n\n\u003cp\u003ePeople born with natural loss-of-function mutations in the ANGPTL3 gene have lower lipid levels and a reduced risk of atherosclerotic cardiovascular disease, meaning they are protected from the artery-clogging process that causes heart attacks and strokes. By recreating that same type of mutation with CRISPR-Cas9 gene editing, CTX310 aims to deliver a similar lifelong benefit as a single treatment.\u003c\/p\u003e\n\n\u003cp\u003eThis article is based on a letter published in the \u003cem\u003eNew England Journal of Medicine\u003c\/em\u003e that provides the 1-year follow-up results for all patients treated with CTX310 in an early clinical trial.\u003c\/p\u003e\n\n\u003ch2 id=\"study-methods\"\u003eHow the Study Was Designed\u003c\/h2\u003e\n\n\u003cp\u003eThe study was a \u003cstrong\u003ephase 1a, open-label, multicenter trial\u003c\/strong\u003e, meaning it was the first stage of human testing, everyone involved knew which treatment was being given, and patients were treated at multiple sites in Australia and New Zealand (registry number ACTRN12623000809639).\u003c\/p\u003e\n\n\u003cp\u003eFrom May 2024 through August 2025, researchers enrolled \u003cstrong\u003e15 adults\u003c\/strong\u003e with lipid disorders that were not adequately controlled. The patients fell into three groups:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eUncontrolled hypercholesterolemia (very high levels of cholesterol)\u003c\/li\u003e\n  \u003cli\u003eModerate or severe hypertriglyceridemia (very high levels of triglycerides, a type of fat in the blood)\u003c\/li\u003e\n  \u003cli\u003eMixed dyslipidemia (both cholesterol and triglycerides elevated)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eEach participant received one infusion of CTX310 at one of five dose levels: 0.1, 0.3, 0.6, 0.7, or 0.8 mg per kilogram of body weight. The number of patients per dose group was small — for example, 2 patients in the lowest-dose group, 3 in the middle groups, and 4 in the highest-dose (0.8 mg\/kg) group, according to the data shown in the trial figures.\u003c\/p\u003e\n\n\u003cp\u003eThe \u003cstrong\u003eprimary end point\u003c\/strong\u003e — the main outcome the study was designed to measure — was safety, specifically adverse events (unwanted medical effects), including dose-limiting toxic effects (side effects severe enough to prevent giving a higher dose). Lipid levels and ANGPTL3 levels were measured as secondary markers of effectiveness, following each patient from before treatment through 1 year afterward.\u003c\/p\u003e\n\n\u003cp\u003eThe results reported here update an earlier publication (Laffin et al., \u003cem\u003eN Engl J Med\u003c\/em\u003e 2025;393:2119-30) that described the early safety and efficacy of CTX310. This new letter adds a full 1-year follow-up for every trial participant.\u003c\/p\u003e\n\n\u003ch2 id=\"how-ctx310-works\"\u003eHow CTX310 Works: The Science Explained\u003c\/h2\u003e\n\n\u003cp\u003eCTX310 is a \u003cstrong\u003elipid nanoparticle-encapsulated CRISPR-Cas9 messenger RNA and guide RNA\u003c\/strong\u003e. In plain language, it is a tiny fat bubble (nanoparticle) that carries two key ingredients into liver cells (hepatocytes):\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eThe genetic instructions (messenger RNA, or mRNA) for making the Cas9 enzyme, and\u003c\/li\u003e\n  \u003cli\u003eA guide RNA that directs Cas9 to the exact spot in the ANGPTL3 gene to be cut.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eOnce inside the liver cell, the Cas9 enzyme makes a precise cut in the DNA. The cell repairs that cut using a process that often introduces a small error, producing a \u003cstrong\u003eloss-of-function mutation\u003c\/strong\u003e — a genetic change that inactivates the ANGPTL3 gene. Because liver cells live a long time and the edit is permanent in those cells, the effect is intended to last many years, potentially a lifetime.\u003c\/p\u003e\n\n\u003cp\u003eCRISPR-Cas9 stands for \u003cstrong\u003eclustered regularly interspaced short palindromic repeats–Cas9 endonuclease\u003c\/strong\u003e — a naturally occurring bacterial system, adapted for medical use, that acts like molecular scissors guided to a specific DNA sequence.\u003c\/p\u003e\n\n\u003cp\u003eThis approach mimics naturally occurring human mutations in the ANGPTL3 gene that are known to be protective against heart disease. People with those natural variants live healthy lives with lower lipid levels, giving researchers confidence that a deliberate version of the same change may also be safe and beneficial.\u003c\/p\u003e\n\n\u003ch2 id=\"safety\"\u003eSafety at 1 Year: What the Researchers Found\u003c\/h2\u003e\n\n\u003cp\u003eThe headline finding for safety is straightforward: \u003cstrong\u003eno dose-limiting toxic effects occurred\u003c\/strong\u003e, and no new safety concerns appeared after the first year of follow-up.\u003c\/p\u003e\n\n\u003cp\u003eTwo serious adverse events were reported earlier in the trial. The investigators considered both to be \u003cstrong\u003eunrelated to CTX310\u003c\/strong\u003e, and one event was later determined to be a preexisting condition. After the initial publication, the researchers report that there were no new serious adverse events and no adverse events of special interest (a category of side effects singled out for close monitoring, such as allergic reactions or liver injury).\u003c\/p\u003e\n\n\u003cp\u003eOne participant did have a \u003cstrong\u003etransient elevation in aminotransferase values\u003c\/strong\u003e (liver enzymes, a sign of possible liver irritation) shortly after treatment. This was already known from the earlier report. Importantly, no other elevations in liver-function measures occurred for the remainder of the trial, meaning CTX310 did not appear to cause lasting liver damage in this small group.\u003c\/p\u003e\n\n\u003cp\u003eFull details of all adverse events throughout the trial were provided in Table S1 of the Supplementary Appendix that accompanies the published letter. It is worth emphasizing that safety results from a 15-patient trial are reassuring but not definitive — rare side effects can only be detected in much larger studies.\u003c\/p\u003e\n\n\u003ch2 id=\"efficacy\"\u003eEffectiveness at 1 Year: Detailed Results\u003c\/h2\u003e\n\n\u003cp\u003eThe key efficacy finding is that \u003cstrong\u003ethe reductions in ANGPTL3 and harmful blood fats were large and, importantly, were sustained at 1 year after a single infusion\u003c\/strong\u003e. This durability over time is the new information this letter adds.\u003c\/p\u003e\n\n\u003cp\u003eAmong the \u003cstrong\u003e4 participants who received the highest dose (0.8 mg per kilogram)\u003c\/strong\u003e, the mean percent changes at 1 year were:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eANGPTL3 (the target protein):\u003c\/strong\u003e down by 78.6% (range across patients, −89.0% to −63.1%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLDL cholesterol (the \"bad\" cholesterol that clogs arteries):\u003c\/strong\u003e down by 52.5% (range, −84.2% to −24.4%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTriglycerides (blood fats linked to heart and pancreas risk):\u003c\/strong\u003e down by 47.8% (range, −77.6% to −14.7%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNon-HDL cholesterol (all cholesterol carried in artery-clogging particles):\u003c\/strong\u003e down by 52.0% (range, −79.4% to −25.2%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHDL cholesterol (the \"good\" cholesterol):\u003c\/strong\u003e down by 23.5% (range, −44.9% to 0.0%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eApolipoprotein B (apoB, the number of artery-clogging particles):\u003c\/strong\u003e down by 37.2% (range, −61.2% to −12.9%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTriglyceride-rich lipoprotein cholesterol (TRL cholesterol, another harmful particle type):\u003c\/strong\u003e down by 71.7% (range, −87.8% to −56.1%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe change in HDL cholesterol is worth explaining. A decline in \"good\" cholesterol might sound bad, but many specialists see it as an expected and generally acceptable effect of treatments that dramatically lower the triglyceride-rich particles, because the same metabolic pathway handles both. The trial did not report any harm associated with this change.\u003c\/p\u003e\n\n\u003cp\u003eTo make the scale of these reductions easier to picture: a 52.5% average drop in LDL cholesterol is in the same range as what many patients achieve with the most potent daily statins or with injectable PCSK9 inhibitors — except here it occurred after one infusion, without ongoing medication.\u003c\/p\u003e\n\n\u003cp\u003eA few additional points from the results:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eThe changes in individual participants at the highest dose varied widely — LDL reductions ranged from 24.4% to 84.2% depending on the person — which shows that individual responses differ.\u003c\/li\u003e\n  \u003cli\u003eChanges in ANGPTL3 levels and lipid biomarkers were shown in Table S2 of the Supplementary Appendix; the percent changes from baseline over time are shown in figures in the letter (Figure 1 and Figure S1).\u003c\/li\u003e\n  \u003cli\u003eThe trial figures plot the mean percent change from baseline for ANGPTL3, LDL cholesterol, triglycerides, and non-HDL cholesterol at each dose level, with standard-error bars showing statistical spread. For the highest three doses, an inset graph in the triglyceride panel displays the same data on an expanded axis, making the sustained pattern easier to see.\u003c\/li\u003e\n  \u003cli\u003eDetails about how representative the trial population was compared with the broader patient population are provided in Table S3.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBecause no p-values were reported in this letter, the results are best interpreted as descriptive evidence of effect size and durability, rather than as formal proof. The wide ranges remind us that this is a small, early-phase study.\u003c\/p\u003e\n\n\u003ch2 id=\"other-approaches\"\u003eOther Gene-Editing Approaches for Lipid Disorders\u003c\/h2\u003e\n\n\u003cp\u003eCTX310 is not the only gene-editing strategy in development for lipid disorders. The letter's authors point out that other investigators are testing a different type of gene editing — \u003cstrong\u003ein vivo base editing\u003c\/strong\u003e — which makes a single-letter change in DNA rather than a double-stranded cut. These programs target a different gene: \u003cstrong\u003ePCSK9 (proprotein convertase subtilisin–kexin type 9)\u003c\/strong\u003e, a protein that regulates how many LDL receptors the liver makes.\u003c\/p\u003e\n\n\u003cp\u003eThe letter cites two notable examples:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eA phase 1 trial of in vivo base editing for heterozygous familial hypercholesterolemia, an inherited condition causing extremely high cholesterol from birth (Wan et al., \u003cem\u003eNature Medicine\u003c\/em\u003e 2026;32:1045-51).\u003c\/li\u003e\n  \u003cli\u003eA trial of a base-editing therapy called VERVE-102, which targets PCSK9 to treat hypercholesterolemia (Vafai et al., \u003cem\u003eN Engl J Med\u003c\/em\u003e 2026;395:648-59).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe letter also references a 2026 American College of Cardiology scientific statement on gene-editing therapy in cardiovascular disease, reflecting how quickly this field is moving and how seriously mainstream cardiology groups are taking it.\u003c\/p\u003e\n\n\u003cp\u003eFor patients, this competitive pipeline is good news: several approaches and target genes are being explored, increasing the odds that at least one will prove safe, durable, and beneficial in larger trials.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Could Mean for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe authors state that CTX310 \"was associated with few adverse events and produced sustained changes in the levels of ANGPTL3 and atherogenic lipoproteins at 1 year, further supporting its potential as a one-time treatment.\"\u003c\/p\u003e\n\n\u003cp\u003ePut simply, this means a patient might one day receive a single infusion that permanently lowers their LDL cholesterol by roughly half or more and their triglycerides by a similar amount, with no need for daily or monthly medication. For patients with severe lipid disorders who cannot tolerate statins or who never reach target levels despite multiple drugs, that would be a transformative option.\u003c\/p\u003e\n\n\u003cp\u003eThe timing of the effect is particularly relevant. Changes in lipid biomarkers after CTX310 may vary according to the type of lipid disorder a patient has. The reductions appear to be reached within the first weeks to months after treatment, and the key message of this report is that \u003cstrong\u003ethey persist at least to the 12-month mark\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eBut durable gene edits also raise the stakes: an effect that lasts is an advantage, yet doctors will want to confirm over many more years that permanent lowering of ANGPTL3 is not linked to any late-appearing problems. The liver is central to countless body functions, so long-term monitoring of liver health and other metabolic effects will be essential before this therapy could be considered for widespread use.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\n\u003cp\u003eThis letter is encouraging, but it is important to understand what it does \u003cstrong\u003enot\u003c\/strong\u003e prove.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVery small sample size.\u003c\/strong\u003e Only 15 adults were treated in this phase 1a trial, and the strongest efficacy numbers come from just 4 patients at the highest dose. A single patient's unusually large or small response can skew the averages.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo control group.\u003c\/strong\u003e The trial was open-label and single-group. There was no comparison group receiving placebo or standard care, so we cannot separate the treatment effect from natural fluctuations or the placebo effect using this design alone.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLimited follow-up window.\u003c\/strong\u003e One year proves durability so far, but not permanence. Whether ANGPTL3 levels remain suppressed at 5 or 10 years needs continued observation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDescriptive statistics only.\u003c\/strong\u003e The letter reports mean percent changes and ranges without p-values, so the findings are descriptive rather than hypothesis-proving.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSelection of patients.\u003c\/strong\u003e The results may not apply equally to every lipid disorder. The authors explicitly note that biomarker changes may vary by lipid-disorder type, which is why the next phase of testing is organized by specific patient subgroups.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRare side effects cannot be excluded.\u003c\/strong\u003e A trial this size cannot detect uncommon safety problems, and the long-term consequences of permanently editing a metabolic gene are unknown.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"next-steps\"\u003eWhat Happens Next: Recommendations and Ongoing Research\u003c\/h2\u003e\n\n\u003cp\u003eThe research is continuing. The authors report that \u003cstrong\u003ephase 1b of the trial is testing a fixed dose of 0.8 mg per kilogram\u003c\/strong\u003e of CTX310 in patients with \u003cstrong\u003erefractory dyslipidemias\u003c\/strong\u003e — lipid disorders that have not responded adequately to existing therapies (ClinicalTrials.gov number, NCT07491172).\u003c\/p\u003e\n\n\u003cp\u003eIn this next phase, efficacy is being assessed in \u003cstrong\u003eseparate cohorts of patients with specific lipid disorders\u003c\/strong\u003e, an acknowledgment that a one-size-fits-all result may not apply across all patient types. These cohorts will give clearer answers about which patients benefit most.\u003c\/p\u003e\n\n\u003cp\u003eFor patients interested in gene-editing therapies for cholesterol, the practical recommendations remain:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eContinue prescribed lipid-lowering medications until a treatment is approved and your doctor advises a change. Gene editing is still experimental and not available outside clinical trials.\u003c\/li\u003e\n  \u003cli\u003eTalk to a lipid specialist or cardiologist if your cholesterol or triglycerides remain uncontrolled despite standard therapy, because you may be a candidate for trials like this one.\u003c\/li\u003e\n  \u003cli\u003eAsk about clinical trial registries (such as ClinicalTrials.gov or the Australia New Zealand Clinical Trials Registry) to find current studies for which you might qualify.\u003c\/li\u003e\n  \u003cli\u003eWait for longer-term data. The 1-year results are promising, but decisions about a permanent genetic change deserve the fullest possible evidence on safety and durability.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eIf phase 1b and subsequent larger trials confirm these findings, CTX310 could eventually represent one of the most significant advances in preventive cardiology in decades — a single treatment that durably addresses the root cause of high lipid levels rather than managing them day by day.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is CTX310 and how does it work?\u003c\/h3\u003e\n\u003cp\u003eCTX310 is an experimental gene-editing therapy given as a single infusion. It uses CRISPR-Cas9 to permanently disable the ANGPTL3 gene in liver cells. That gene normally helps block the breakdown of blood fats. Disabling it lowers levels of harmful lipids, including LDL cholesterol and triglycerides.\u003c\/p\u003e\n\u003ch3\u003eHow effective was CTX310 after one year in the trial?\u003c\/h3\u003e\n\u003cp\u003eIn a small early trial, 15 patients received one infusion. Among the 4 patients given the highest dose (0.8 mg\/kg), mean reductions at 1 year were 78.6% for ANGPTL3 protein, 52.5% for LDL cholesterol, and 47.8% for triglycerides. Individual responses varied widely, and results are only descriptive.\u003c\/p\u003e\n\u003ch3\u003eWas CTX310 safe in the one-year study?\u003c\/h3\u003e\n\u003cp\u003eNo dose-limiting toxic effects occurred, and no new safety concerns appeared during the first year. Two serious adverse events were reported earlier and were considered unrelated to CTX310. One patient had a temporary rise in liver enzymes. A 15-patient trial cannot detect rare side effects.\u003c\/p\u003e\n\u003ch3\u003eWho might be eligible for this kind of gene-editing therapy?\u003c\/h3\u003e\n\u003cp\u003eThis trial enrolled adults with severe lipid disorders not adequately controlled by standard therapy, including very high cholesterol, very high triglycerides, or both. CTX310 is experimental and only available in clinical trials. Talk to a lipid specialist or cardiologist to see if you might qualify for similar trials.\u003c\/p\u003e\n\u003ch3\u003eHow long does the effect of CTX310 last?\u003c\/h3\u003e\n\u003cp\u003eIn the trial, reductions in LDL cholesterol, triglycerides, and ANGPTL3 were still present at 12 months after a single infusion. The edit is permanent in liver cells, but whether the effect lasts 5 or 10 years is as yet unknown and requires continued observation.\u003c\/p\u003e\n\u003ch3\u003eWhat are the main limitations of the CTX310 study?\u003c\/h3\u003e\n\u003cp\u003eThe study included only 15 adults, and the strongest results came from 4 patients at the highest dose. It had no control group, followed patients for only one year, and reported descriptive statistics without p-values. Results may vary by lipid disorder type, and rare side effects cannot be excluded.\u003c\/p\u003e\n\u003ch3\u003eShould I get a second opinion before joining a CTX310 gene-editing trial for severe cholesterol that isn't controlled by statins?\u003c\/h3\u003e\n\u003cp\u003eFor severe lipid disorders that remain uncontrolled on standard therapy, a second opinion can help determine whether experimental gene-editing treatment such as CTX310 is a reasonable next step. Current evidence comes from only 15 patients followed for one year; at the highest dose, ANGPTL3 fell by 78.6% and LDL cholesterol by 52.5%, but no control group was included and long-term safety is unknown. Existing lipid-lowering medications should be continued until a treatment is approved. A second opinion can confirm that all established options have been considered. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research published as a letter (Correspondence) in \u003cem\u003eThe New England Journal of Medicine\u003c\/em\u003e.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOriginal title:\u003c\/strong\u003e \"Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310\"\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAuthors:\u003c\/strong\u003e Luke J. Laffin, M.D., Stephen J. Nicholls, M.B., B.S., Ph.D., Russell S. Scott, M.B., Ch.B., Ph.D., Peter M. Clifton, M.B., B.S., Ph.D., Renate Koops, M.D., Ashish Sarraju, M.D., Shweta Singh, Ph.D., Qiuqing Wang, M.S., Kathy Wolski, M.P.H., Huansheng Xu, Ph.D., Jen Nielsen, M.S., Naimish Patel, M.D., Jason M. Duran, M.D., Ph.D., and Steven E. Nissen, M.D. (Laffin and Nicholls contributed equally to the letter.)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJournal:\u003c\/strong\u003e \u003cem\u003eNew England Journal of Medicine\u003c\/em\u003e, published online August 28, 2026; DOI: 10.1056\/NEJMc2609825\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTrial registrations:\u003c\/strong\u003e ACTRN12623000809639 (Australia New Zealand Clinical Trials Registry) and NCT07491172 (ClinicalTrials.gov)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunding and disclosures:\u003c\/strong\u003e The trial was supported by CRISPR Therapeutics, the company developing CTX310. Disclosure forms from the authors are available with the full text of the letter at NEJM.org. Investigators are affiliated with the Cleveland Clinic Coordinating Center for Clinical Research, Cleveland; the Victorian Heart Institute, Melbourne, Australia; New Zealand Clinical Research, Christchurch, New Zealand; Royal Adelaide Hospital, Adelaide, Australia; Aotearoa Clinical Trials, Auckland, New Zealand; and CRISPR Therapeutics, Boston.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrior related publication:\u003c\/strong\u003e Laffin LJ, Nicholls SJ, Scott RS, et al. Phase 1 trial of CRISPR-Cas9 gene editing targeting ANGPTL3. \u003cem\u003eN Engl J Med\u003c\/em\u003e 2025;393:2119-30.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research and is provided for educational purposes. It does not constitute medical advice. Anyone considering gene-editing therapy should discuss risks, benefits, and alternatives with their own physician.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47545212076188,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/fr\/products\/a-one-time-gene-editing-treatment-for-high-cholesterol-shows-strong-results-at-1-year-what-the-new-ctx310-data-mean","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}